Mazdutide: A Breakthrough in Diabetes and Weight Loss Treatment
Shipping: We offer reliable shipping options both domestically and internationally. All orders are processed within 1-2 business days. Shipping times vary depending on your location, and you will receive a tracking number once your order has shipped. Please note that international customers are responsible for ensuring that peptide products comply with their country’s import regulations.
Returns: Due to the specialized nature of our products, we do not accept returns or exchanges. If you receive a damaged or incorrect item, please contact our customer support team within 7 days of delivery. We will work to resolve the issue as quickly as possible, either by sending a replacement or providing a refund if applicable. For additional questions about shipping or returns, please reach out to our support team.
Buy It With
Quick Buy
Buy It With
Buy Hexarelin Peptide - Boost Muscle Growth & Fat Loss
$34.95 USD
$40.00 USD
Buy It With
Quick Buy
The Ultimate Guide to Mazdutide: Efficacy, Safety, and User Experiences in Managing Diabetes and Obesity
Mazdutide (also known as IBI362 or LY3305677) is a dual receptor agonist that affects both GLP-1 and glucagon receptors[12,13]. This novel mechanism provides potential advantages for type 2 diabetes and obesity treatment, offering metabolic benefits beyond those seen with current GLP-1 medications like semaglutide (Ozempic) or tirzepatide (Mounjaro).
The clinical trial results have demonstrated significant efficacy in both glycemic control and weight reduction.
Key Clinical Findings
Clinical trials have demonstrated that Mazdutide achieves 6-13% body weight reduction within 24 weeks through its dual GLP-1/glucagon receptor mechanism. Unlike traditional GLP-1 agonists that primarily suppress appetite, Mazdutide's glucagon activation promotes active fat metabolism.
The most frequently reported adverse events include gastrointestinal symptoms, which typically resolve as patients adjust to treatment. Phase 3 trials are currently underway, with initial regulatory approval anticipated in China. Comparative efficacy data suggests Mazdutide may exceed semaglutide's weight loss effects while remaining less potent than the triple agonist retatrutide.
What is Mazdutide?
Mazdutide (IBI362) represents a new class of incretin-based therapy utilizing dual GLP-1/glucagon receptor activation. This investigational drug targets multiple metabolic pathways to address both hyperglycemia and obesity, conditions that often coexist in patients with type 2 diabetes.
Mechanism Overview:
- Glycemic Regulation – Enhances insulin secretion and reduces hepatic glucose output
- Weight Management – Reduces caloric intake while increasing energy expenditure
- Metabolic Parameters – Improves lipid profiles, hepatic function, and cardiovascular markers
The dual agonist approach differentiates Mazdutide from first-generation GLP-1 receptor agonists by combining appetite regulation with enhanced metabolic rate through glucagon receptor activation (Hope et al., 2021).
The pharmacological profile suggests potential advantages in achieving sustained weight loss while maintaining glycemic control.
How Does Mazdutide Work: Mechanism of Action
Dual Receptor Activation (GLP-1 & Glucagon)
GLP-1 Receptor Activation
The GLP-1 component stimulates glucose-dependent insulin secretion, delays gastric emptying to enhance satiety, suppresses postprandial glucagon release, and reduces appetite through central nervous system pathways. These effects contribute to improved glycemic control and reduced caloric intake.
Glucagon Receptor Activation
Glucagon receptor stimulation increases energy expenditure through enhanced thermogenesis, promotes hepatic fat oxidation reducing liver steatosis, and preserves lean body mass during weight loss. This metabolic activation distinguishes Mazdutide from GLP-1 monotherapy.
Clinical Significance: The dual receptor approach addresses both sides of the energy balance equation — reducing intake through GLP-1 while increasing expenditure via glucagon activation. This mechanism may provide superior metabolic outcomes compared to selective GLP-1 receptor agonists.
Clinical Effect: How Effective Is Mazdutide?
1. Blood Sugar Control (Diabetes Management)
Clinical trials have demonstrated significant reductions in HbA1c, fasting glucose, and postprandial glucose levels[12]. Mazdutide showed comparable or superior efficacy to dulaglutide (Trulicity) in head-to-head comparisons. The medication helps stabilize blood glucose fluctuations, reducing both hyperglycemic peaks and hypoglycemic episodes.
Weight Loss Effects
Mazdutide has shown robust weight reduction in clinical studies:
Phase 2 trials reported mean weight loss ranging from 6% to 13% of baseline body weight over 24 weeks (Ji et al 2021, 2022). Non-diabetic patients demonstrated even greater weight reduction in some cohorts. The efficacy exceeds that of earlier GLP-1 agonists including liraglutide and dulaglutide[14].
Mechanistic Advantage: The dual agonist design enables both reduced caloric intake (via GLP-1) and increased energy expenditure (via glucagon), addressing weight loss through complementary pathways rather than appetite suppression alone.
Cardiometabolic Benefits
Secondary endpoints in clinical trials have shown improvements in blood pressure parameters, lipid profiles including LDL cholesterol and triglycerides, and markers of hepatic steatosis. These metabolic improvements may contribute to reduced cardiovascular risk in the target population.
Cardiovascular Impact and Long-term Implications
- Possible cardiovascular benefits: Early clinical data indicate that Mazdutide could improve lipid profiles (e.g., LDL cholesterol reduction) and decrease arterial stiffness, lowering cardiovascular risk in type 2 diabetes patients (source: Innovent Biologics trial summaries).
- Risk of hypoglycemia: Mazdutide, unlike certain diabetes medications, has low risk for hypoglycemia when on monotherapy, though it should be used cautiously when combining with insulin or sulfonylureas.
- Long-term bone health: There is no specific data that has been published indicating any association between Mazdutide and changes in bone density, however GLP-1 agonists in general are under investigation for possible effects on bone metabolism because of the stress to skeletal health induced by weight loss.
How Does Mazdutide Compare to Other Weight Loss Drugs?
| Drug | GLP-1 Agonist | GIP Agonist | Glucagon Activation | Weight Loss |
|---|---|---|---|---|
| Ozempic (semaglutide) | ✅ Yes | ❌ No | ❌ No | ⭐⭐⭐ |
| Tirzepatide (Mounjaro) | ✅ Yes | ✅ Yes | ❌ No | ⭐⭐⭐⭐ |
| Retatrutide | ✅ Yes | ✅ Yes | ✅ Yes | ⭐⭐⭐⭐⭐ |
| Mazdutide | ✅ Yes | ❌ No | ✅ Yes | ⭐⭐⭐⭐ |
Tirzepatide vs. Mazdutide: Tirzepatide activates the GIP response while Mazdutide activates the glucagon response. GIP plays a role in insulin sensitivity and glucagon increases fat burning. Mazdutide might be superior for direct fat loss, though Tirzepatide might be better for insulin resistance (Jastreboff et al., 2022; Klein et al., 2023).
Mazdutide vs Retatrutide: Retatrutide (a triple agonist) has demonstrated even greater weight loss (up to 24% body weight loss in studies), but Mazdutide remains a potent weight loss agent with a potentially better safety profile [Friedrichsen 2023].
Safety Profile: Side Effects & Risks
Common Side Effects
Mazdutide can cause gastrointestinal side effects like other GLP-1 drugs, including[18]:
- ✅ Nausea (the most common, typically mild and resolves over time)
- ✅ Diarrhea (some users may experience loose stools)
- ✅ Vomiting (less common but possible)
💡 The majority of side effects are temporary and will improve as your body adjusts to the medication (Gorgojo-Martinez et al 2023).
Rare but Serious Risks
- Gastroparesis (delayed stomach emptying) – May lead to extreme bloating and belly pain.
- Cardiovascular effects possible – Some people report feeling like their heart beats faster.
- No known long-term effects – More research necessary in relation to bone health & heart disease risk.
🚨 Who SHOULD NOT Use Mazdutide?
- Individuals with personal history of medullary thyroid carcinoma.
- Individuals with severe GI/GU disorders.
- Pregnant and lactating women (safety not established).
User Experiences & Reviews
Reported Benefits
Clinical trial participants and early access patients have reported several positive outcomes. Weight reduction becomes noticeable within the first month of treatment, with continued progress throughout the study period. Appetite control improves significantly, making adherence to caloric restrictions more manageable. Glycemic stability reduces the frequency of both hyperglycemic and hypoglycemic episodes. Some patients also report improved energy levels, potentially related to better metabolic control and weight reduction.
Common Challenges
Gastrointestinal tolerance – Initial nausea and digestive discomfort are frequently reported during the first 2-4 weeks
Cardiovascular sensations – A minority of patients experience palpitations or perceived increased heart rate
Injection site reactions – Mild erythema or pruritus at injection sites typically resolves without intervention
Cost considerations – Limited insurance coverage in available markets results in significant out-of-pocket expenses
Long-term data – Some patients express concern about the limited long-term safety data currently available
Clinical experience suggests most adverse effects are manageable with appropriate patient education and support. Compare with other GLP-1 medications.
Individual responses vary; some patients report faster onset of weight loss compared to previous GLP-1 therapy, though controlled comparative data is limited.
Clinical Development: What Is Next for Mazdutide?
- Currently in Phase 3 clinical trials (the last step before approval).
- Anticipated initial approvals in China to treat diabetes.
- Global approval timeline unclear at present, but could compete with Tirzepatide within the next several years.
- Pediatric trials: Early studies are testing the safety and efficacy of Mazdutide in children with obesity and type 2 diabetes, with results expected in 2027.
- Combination therapy: Mazdutide is being evaluated in combination with SGLT2 inhibitors (e.g., dapagliflozin) in the attempt to optimize glycemic control and weight loss.
- Non-alcoholic steatohepatitis (NASH): Mazdutide is also in the clinical development for treatment of NASH, and promising data were obtained in an early phase of clinical trials.
The exact timeline remains uncertain as regulatory processes can be lengthy.
Conclusion: Clinical Considerations for Mazdutide
Therapeutic Advantages:
Mazdutide offers several potential benefits based on current clinical data. The dual receptor mechanism addresses both hyperglycemia and obesity through complementary pathways. Weight loss efficacy appears superior to first-generation GLP-1 agonists in comparative trials. The medication may provide additional metabolic benefits including improvements in hepatic and cardiovascular parameters. The unique glucagon component differentiates it from existing dual incretin therapies.
Limitations and Considerations:
Several factors warrant consideration when evaluating Mazdutide. Gastrointestinal tolerability remains a concern, particularly during treatment initiation. The medication is not yet widely available pending regulatory approvals. Long-term safety data beyond current trial durations is still being collected. Weekly subcutaneous administration may affect patient preference compared to oral alternatives. Post-marketing surveillance data remains limited given the drug's investigational status.
Clinical Perspective:
Mazdutide represents an evolution in incretin-based therapy for metabolic disease. The dual agonist approach shows promise for addressing the complex pathophysiology of type 2 diabetes with obesity. Comparative efficacy data suggests potential advantages over semaglutide for weight reduction (Wilding et al 2021; Ghusn et al 2022), though the triple agonist retatrutide may offer superior weight loss outcomes. Individual patient factors including comorbidities, treatment goals, and tolerance will guide therapeutic selection.
Treatment decisions should be individualized based on comprehensive clinical assessment and shared decision-making between patients and healthcare providers.
FAQs: Mazdutide at a Glance
What is Mazdutide used for?
Mazdutide (IBI362) is a dual GLP-1/GIP receptor agonist developed to treat type 2 diabetes and to aid in weight loss by managing appetite and blood sugar levels.
Does Mazdutide cure diabetes?
No, Mazdutide does not cure diabetes, but it can help manage blood sugar levels and may increase insulin sensitivity when part of a comprehensive treatment plan.
How long will you need to take Mazdutide?
Mazdutide is administered as a long-term medication, like other GLP-1 receptor agonists, to control blood sugar levels over time and promote continuous weight loss.
Who should avoid taking Mazdutide?
Mazdutide may not be suitable for patients with a history of thyroid cancer, pancreatitis, or severe gastrointestinal symptoms. It's also not recommended for use during pregnancy or while breastfeeding.
What are the side effects of Mazdutide?
Common side effects include nausea, vomiting, diarrhea, decreased appetite, and mild gastrointestinal discomfort. These effects typically become less severe as your body adapts to the drug.
How does Mazdutide differ from Semaglutide or Tirzepatide?
While functioning similarly to Semaglutide and Tirzepatide, Mazdutide has a novel dual-agonist mechanism that could increase weight and glucose benefits.
How is Mazdutide administered?
Subcutaneous injections are used to administer Mazdutide; in general, dosages are given once a week as prescribed by your healthcare provider.
Can it be used solely for weight reduction?
Although it exhibits weight-loss properties, it is primarily intended for diabetes management. However, some people may receive the drug specifically for weight loss under medical supervision.
Can Mazdutide be combined with other drugs?
It can work in combination with other drugs like insulin, oral diabetic medicines, or weight-loss medications. However, professional healthcare consultation should be sought before combining medications.
How does dual mechanism of action of Mazdutide work?
Mazdutide is acting as an agonist for both GLP-1 and glucagon receptors, thus, inducing insulin secretion, delaying gastric emptying, and stimulating energy expenditure with the combined positive effects on glucose handling and fat loss.
Is Mazdutide available as an oral product?
Mazdutide is not in the form of an oral drug, it is only in the form of a subcutaneous injection.
Is it safe for PCOS weight gain? Can I use mazdutide?
It does not have FDA approval for PCOS and is not indicated for such, but given its success in obesity studies, there has been increased off-label use of this agent in PCOS to address weight management.
How much Mazdutide do people take?
The dosing begins with 2 mg once a week, and is titrated to 6 mg or higher depending on tolerability and response, in accordance with phase 3 trial protocols.
Does Mazdutide react with Alcohol?
There are no known interactions, but alcohol in large quantities may exacerbate GI side effects or alter blood sugar control, use with caution.
References & Further Reading
Clinical Studies and Reviews on Mazdutide
-
Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes
Source: Diabetes Care
Link: Diabetes Journals
Summary: This study assesses Mazdutide's safety and efficacy in Chinese type 2 diabetic patients. Parameters examined include pharmacodynamic outcomes such as FPG, insulin, and C-peptide changes. -
A Phase 2 Randomised Controlled Trial of Mazdutide in Chinese Adults With Overweight or Obesity
Source: Nature Communications
Link: Nature
Summary: This clinical trial evaluates 24-week doses of Mazdutide up to 6mg in Chinese overweight adults. Weight loss outcomes were key focus areas. -
A dual GLP-1/glucagon receptor agonist mazdutide (IBI362) for treatment of NAFLD/NASH
Source: PubMed Central
Link: PMC
Summary: We characterized the safety and weight loss efficacy of up to 6 mg of Mazdutide over 12 weeks with mean body weight loss up to 6.4% in Chinese adults with overweight or obesity. -
Mazdutide in the Treatment of Overweight or Obesity in Diabetic or Prediabetic Participants and Non-diabetic Overweight or Obese Adults
Source: PubMed Central
Link: PMC
Summary: This review summarizes the evidence of the effect of Mazdutide versus placebo on weight loss in adults with and without diabetes. -
Mazdutide (IBI362) Phase 2 High Dose 9mg Clinical Trial in Obesity
Source: Innovent Biologics
Link: Innovent Biologics
Summary: Information about a phase 2 clinical study of Mazdutide high dose (9mg) in obese subjects and its weight loss effect and safety profiles. -
Mazdutide in Diabetic and Nondiabetic Subjects for Weight Reduction – A Post Hoc Analysis
Source: Frontiers in Endocrinology
Link: Frontiers
Background: This study conducts a synthesis of evidence from RCTs to estimate the efficacy and safety of Mazdutide versus placebo with regard to body weight reduction in adult diabetic and non-diabetic participants.
Disclaimer:
This guide is for informational purposes only and is not a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medication or medical condition. Everyone's body responds differently to treatments and only a doctor can determine what's best for you. Your health and safety come first! 🚑💊
Scientific References
1. Zeng, Q., Li, N., Pan, X. F., Chen, L., & Pan, A. (2021). Clinical management and treatment of obesity in China. Lancet Diabetes Endocrinol., 9, 393–405.
2. Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol. 2021;9:373-392. doi:10.1016/S2213-8587(21)00143-0
6. Ghusn, W. et al. (2022). Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw. Open, 5, e2231982.
7. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183
8. Jastreboff, A. M. et al. (2022). Tirzepatide once weekly for the treatment of obesity. N Engl. J. Med., 387, 205–216.
9. Friedrichsen MH et al. Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist. Mol Metab. 2023;78:101801.
10. Klein, T., Augustin, R., & Hennige, A. M. (2023). Perspectives in weight control in diabetes.
11. Alba M, Yee J, Frustaci ME, Samtani MN, Fleck PE. Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ ‐64565111... Clin Obes. 2021;11:e12432
12. Ji, L. et al. (2021). IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine, 39, 101088.
13. Ji L et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity. EClinicalMedicine 2022;54:101691. doi:10.1016/j.eclinm.2022.101691
14. Jepsen MM, Christensen MB. (2021). Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 26:231-243.
18. Gorgojo-Martínez JJ et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists. J Clin Med. 2023;12:145.
19. Lau, D. C. W., Batterham, R. L., & le Roux, C. W. (2022). Pharmacological profile of once-weekly injectable semaglutide for chronic weight management. Expert Rev. Clin. Pharmacol., 15, 251–267. doi:10.1080/17512433.2022.2067338
20. Rosenstock J, Blueher M, Schmid B, Hoefler J, Hennige A. Multiple dose-ranging study of the novel glucagon/GLP-1 receptor dual agonist BI 456906... Diabetologia. 2022;65:S314-S315.
21. Hope DCD, Vincent ML, Tan TMM. Striking the balance: GLP-1/Glucagon Co-agonism as a treatment strategy for obesity. Front Endocrinol. 2021;12:1-11. doi:10.3389/fendo.2021.01971
22. Ambery P et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes. Lancet. 2018;391:2607-2618.
23. Tillner, J. et al. (2019). A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes. Metab., 21, 120–128.
24. Jungnik A et al. Phase I studies of the safety, tolerability, PK and PD of the dual GCGR/GLP-1R agonist BI 456906. Diabetes Obes Metab. 2022 [epub ahead]
Our Story, Our Promise
At PeptideHackers, we’re committed to advancing research by providing high-quality peptides for scientific and research purposes. We ensure the highest standards and transparency in every product, supporting your research with science-backed solutions. Welcome to PeptideHackers.
Glutathione
Glutathione is a powerful antioxidant that helps protect your body from free radicals and oxidative stress. It also supports cellular health and the immune system.
Ipamorelin
Ipamorelin is a peptide that stimulates the release of growth hormone from the pituitary gland. It's often used to support muscle growth, fat loss, and overall recovery by promoting the body's natural hormone production.
Kisspeptin
Kisspeptin is a peptide that plays a crucial role in regulating the reproductive hormone axis by stimulating the release of gonadotropin-releasing hormone (GnRH). It is essential for the onset of puberty and fertility.
Frequently Asked Questions
-
Due to the sensitive nature of our research products, we do not accept returns or exchanges. However, if you receive a damaged or incorrect item, please contact our customer support team within 7 days of receiving your order, and we will work to resolve the issue.
-
Research peptides are short chains of amino acids designed for laboratory and scientific research purposes only. They are not intended for human or animal use.
-
Peptides should be stored in a cool, dry place. For long-term storage, refrigerate at 4°C, and for even longer preservation, freezing at -20°C is recommended.
-
Yes, we provide a Certificate of Analysis (COA) for every batch of peptides, detailing the purity and composition to ensure research quality.